Art. -Nr.: HY-B1245

Salsalate

(Synonyms: Salicylsalicylic acid; Disalicylic acid)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Salsalate is a potent antirheumatic drug with oral activity that reduces irritation during gastric absorption and avoids direct inhibition of cyclooxygenase. Salsalate not only has significant anti-inflammatory effects, but also reduces blood sugar levels, improves insulin resistance, and reduces the expression of cytokines. Salsalate can protect mice from metabolic disorders caused by high-fat diet and effectively improve the symptoms of type 2 diabetes, atherosclerosis and non-alcoholic steatohepatitis^{[2 ]}.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.61%
CAS. Nr.: 552-94-3
Formel: C₁₄H₁₀O₅
Molecular Weight:258.23

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Salsalate Chemical Structure

CAS. Nr.: 552-94-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Salsalate (1 mM, 72 h) inhibits the proliferation of bone marrow-derived macrophages by phosphorylating HMGCoA reductase^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

BMDMs
Concentration:

1 mM
Incubation Time:

90 min
Result:

Increased phosphorylation of ACC in macrophages from WT mice but not from AMPKβ1^-/- mice.

Cell Viability Assay^[1]

Cell Line:

BMDMs
Concentration:

1 mM
Incubation Time:

72 h
Result:

Inhibited proliferation of WT macrophages but not AMPKβ1^-/- mice.

In Vivo

Salsalate (2.5 g/kg feed, orally, daily, for 6 weeks) inhibits macrophage proliferation and atherosclerosis in mice through an AMPKβ1-dependent pathway^[1].
Salsalate (0.5%, orally, daily, for 40 days) protects mice from metabolic dysfunction induced by a high-fat diet by activating mitochondrial uncoupling and the Sln/Serca2a axis in skeletal muscle thermogenesis^[2].
Salsalate (0.33%, orally, daily, for 40 weeks) improves dyslipidemia and insulin resistance in mice, enhances diet-induced non-alcoholic steatohepatitis, reduces microvesicular and macrovesicular steatosis in the liver, and decreases the incidence of liver inflammation and fibrosis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ApoE^-/- and LDLr^-/- mice and their corresponding germline or bone marrow AMPKβ1-deficient^+/+^[1]
Dosage:

Western diet containing 2.5 g/kg salsalate; daily; 6 weeks
Administration:

Oral
Result:

Reduced atherosclerotic plaques in the aortic root of ApoE^-/- mice, and the reduction in atherosclerosis was associated with reduced macrophage proliferation, reduced plaque lipid content, and reduced serum cholesterol.

Animal Model:

High-fat diet mice^[2]
Dosage:

0.5%; daily; 40 days
Administration:

Oral
Result:

Reduced lipid accumulation in liver and epididymal white adipose tissue (eWAT), suppressed hepatic gluconeogenesis, improved insulin signaling in eWAT, increased the expression of genes related to glucose and fatty acid transport and oxidation in skeletal muscle, enhanced the expression of genes for mitochondrial uncoupling and electron transport, boosted skeletal muscle sarcolipin (Sln) and sarcoplasmic reticulum Ca²⁺ ATPase 2 (Serca2), and improved whole-body glucose homeostasis.

Animal Model:

CETP mice were fed a high-fat and high-cholesterol diet^[3]
Dosage:

0.33% in HFC; daily; 20 weeks
Administration:

Oral
Result:

Improved dyslipidemia and insulin resistance, improved diet-induced NASH, reduced liver microvesicular and macrovesicular fatty degeneration, reduced the occurrence of liver inflammation and fibrosis, activated genes controlled by PPAR-α, PPARγ coactivator 1β, RXR-α and inhibited transcription factor MLXIPL/ChREBP, downregulated NF-κB pathway, and downregulated TGF-β signaling pathway.

Chemical Information

CAS. Nr. 552-94-3
Appearance Solid
Molecular Weight 258.23
Formel C₁₄H₁₀O₅
Color White to yellow
SMILES

O=C(OC1=CC=CC=C1C(O)=O)C2=CC=CC=C2O
Synonyms

Salicylsalicylic acid; Disalicylic acid
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Biomacromolecules

Investigation of Basolateral Targeting Micelles for Drug Delivery Applications in Polycystic Kidney Disease. [Abstract]

2024 May 13;25(5):2749-2761. PMID: 38652072
Cell Mol Bioeng

Combining Metformin and Drug-Loaded Kidney-Targeting Micelles for Polycystic Kidney Disease. [Abstract]

2022 Dec 22;16(1):55-67. PMID: 36660586

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (387.25 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8725 mL

19.3626 mL

38.7252 mL

5 mM

0.7745 mL

3.8725 mL

7.7450 mL

10 mM

0.3873 mL

1.9363 mL

3.8725 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Emily A Day, et al. Salsalate reduces atherosclerosis through AMPKβ1 in mice.Mol Metab.2021 Nov:53:101321. [Content Brief]

[2]. Li Nie, et al. Salsalate Activates Skeletal Muscle Thermogenesis and Protects Mice from High-Fat Diet Induced Metabolic Dysfunction. EBioMedicine. 2017 Sep:23:136-145. [Content Brief]

[3]. Wen Liang, et al. Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. Br J Pharmacol. 2015 Nov;172(22):5293-305. [Content Brief]

[4]. Murthy SN, et al. Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats. Diabetes. 2010;59(12):3240-3246. [Content Brief]

[5]. Scheiman JM, et al. Gastroduodenal mucosal damage with salsalate versus aspirin: results of experimental models and endoscopic studies in humans. Semin Arthritis Rheum. 1990;20(2):121-127. [Content Brief]

[6]. González F, et al. Salicylate administration suppresses the inflammatory response to nutrients and improves ovarian function in polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2020;319(4):E744-E752. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8725 mL	19.3626 mL	38.7252 mL	96.8129 mL
	5 mM	0.7745 mL	3.8725 mL	7.7450 mL	19.3626 mL
	10 mM	0.3873 mL	1.9363 mL	3.8725 mL	9.6813 mL
	15 mM	0.2582 mL	1.2908 mL	2.5817 mL	6.4542 mL
	20 mM	0.1936 mL	0.9681 mL	1.9363 mL	4.8406 mL
	25 mM	0.1549 mL	0.7745 mL	1.5490 mL	3.8725 mL
	30 mM	0.1291 mL	0.6454 mL	1.2908 mL	3.2271 mL
	40 mM	0.0968 mL	0.4841 mL	0.9681 mL	2.4203 mL
	50 mM	0.0775 mL	0.3873 mL	0.7745 mL	1.9363 mL
	60 mM	0.0645 mL	0.3227 mL	0.6454 mL	1.6135 mL
	80 mM	0.0484 mL	0.2420 mL	0.4841 mL	1.2102 mL
	100 mM	0.0387 mL	0.1936 mL	0.3873 mL	0.9681 mL

Keywords

Salsalate

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Salsalate

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Salsalate

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Salsalate Related Classifications

HY-B1245 Related Classifications